Insmed (INSM) Stock Price, News & Analysis

Company Overview

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company’s expertise lies in inhaled and systemic drug-delivery technologies designed to target diseases with high unmet medical needs. Insmed’s lead product, Arikayce® (amikacin liposome inhalation suspension), is the first and only FDA-approved therapy for refractory Mycobacterium avium complex (MAC) lung disease in adults, representing a significant advance in treating this life-threatening pulmonary condition.

Arikayce, administered via nebulizer, employs liposomal encapsulation to deliver high concentrations of antibiotic directly to the site of infection while minimizing systemic exposure. Initially approved in the United States, the product has since received marketing authorizations in Europe, Canada, Japan and Australia, establishing Insmed’s footprint in key global markets. The company works closely with pulmonologists, infectious disease specialists and patient advocacy groups to support disease awareness, diagnosis and access to therapy.

Beyond Arikayce, Insmed maintains a growing pipeline of investigational therapies targeting serious rare diseases in pulmonology, nephrology and genetic disorders. Its research programs leverage proprietary delivery platforms and robust preclinical models to advance novel candidates toward regulatory milestones. Collaborations with academic institutions and industry partners further enhance Insmed’s ability to expand its portfolio and address additional high-impact indications.

Founded in 2005 and headquartered in Bridgewater, New Jersey, Insmed operates research, development and commercial teams across the United States and Europe. Under the leadership of President and Chief Executive Officer Will Lewis, the company emphasizes patient-centric innovation, rigorous clinical science and strategic regulatory planning. Insmed’s global organization continues to grow, fostering a network of experts committed to improving outcomes for patients affected by rare and serious diseases.

Key Stats

• Today's Range: $95.72 to $98.53
• 50-Day Range: $65.08 to $105.90
• 52-Week Range: $60.40 to $106.83
• Volume: 1.76 million shs
• Average Volume: 2.31 million shs
• Market Capitalization: $18.69 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $106.80
• Consensus Rating: Buy

Insmed Stock Analysis - MarketRank™

Insmed scored higher than 83% of companies evaluated by MarketBeat, and ranked 175th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Insmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 17 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Insmed has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Insmed are expected to grow in the coming year, from ($4.56) to ($2.89) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Insmed is -16.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Insmed is -16.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Insmed has a P/B Ratio of 61.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.33% of the float of Insmed has been sold short.

Short Interest Ratio / Days to Cover

Insmed has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Insmed has recently decreased by 33.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Insmed does not currently pay a dividend.

Dividend Growth

Insmed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.58

Percentage of Shares Shorted

6.33% of the float of Insmed has been sold short.

Short Interest Ratio / Days to Cover

Insmed has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Insmed has recently decreased by 33.28%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.23

News Sentiment

Insmed has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Insmed this week, compared to 12 articles on an average week.

Search Interest

21 people have searched for INSM on MarketBeat in the last 30 days. This is an increase of 425% compared to the previous 30 days.

MarketBeat Follows

7 people have added Insmed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Insmed insiders have sold 21,318.50% more of their company's stock than they have bought. Specifically, they have bought $201,694.00 in company stock and sold $43,199,826.00 in company stock.

Percentage Held by Insiders

Only 3.00% of the stock of Insmed is held by insiders.

INSM Stock Analysis - Frequently Asked Questions

How have INSM shares performed this year?

Insmed's stock was trading at $69.04 at the beginning of 2025. Since then, INSM shares have increased by 42.7% and is now trading at $98.50.

How were Insmed's earnings last quarter?

Insmed, Inc. (NASDAQ:INSM) announced its quarterly earnings data on Thursday, May, 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by $0.06. The company's quarterly revenue was up 22.9% compared to the same quarter last year.
Read the conference call transcript.

How do I buy shares of Insmed?

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INSM
• CIK: 1104506
• Web: www.insmed.com
• Phone: 908-977-9900
• Fax: 732-438-0381
• Employees: 1,271
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $106.80
• High Stock Price Target: $120.00
• Low Stock Price Target: $92.00
• Potential Upside/Downside: +8.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$913.77 million
• Net Margins: -265.93%
• Pretax Margin: -264.87%
• Return on Equity: -446.98%
• Return on Assets: -52.70%

Debt

• Debt-to-Equity Ratio: 11.38
• Current Ratio: 5.86
• Quick Ratio: 5.44

Sales & Book Value

• Annual Sales: $363.71 million
• Price / Sales: 51.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.60 per share
• Price / Book: 61.56

Miscellaneous

• Outstanding Shares: 189,710,000
• Free Float: 184,022,000
• Market Cap: $18.69 billion
• Optionable: Optionable
• Beta: 0.90